MedTrace Logo

A Study of Single Dose of LP-003 in Adolescent Subjects

NCT07148557 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-02-17

No results posted yet for this study

Summary

This is a single-center, open-label, phase Ib clinical study to evaluate the safety, pharmacokinetics and pharmacodynamic characteristics of LP-003 injection in adolescent subjects aged 12-18 years.

Conditions

  • Allergic Diseases

Interventions

BIOLOGICAL

LP-003 Dose 1 (Single)

A single dose of LP-003 (400 mg/dose) was SC

BIOLOGICAL

LP-003 Dose 2 (Single)

A single dose of LP-003 (600 mg/dose) was SC

Sponsors & Collaborators

  • Longbio Pharma

    lead INDUSTRY

Principal Investigators

  • Huan Zhou · The First Affiliated Hospital of Anhui Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-05-31
Completion
2026-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07148557 on ClinicalTrials.gov